Compensation
- Develop and drive the organization’s compensation philosophy
- Conduct market analysis and benchmarking to ensure competitive pay practices
- Oversee job evaluations, salary structures, incentive plans, and annual compensation reviews
- Manage bi-annual Pay Equity analysis and compensation reviews using Pave (HRIS)
- Ensure compliance with local labor laws and regulations regarding compensation
- Drive transparency and education to employees
- Executive Compensation exposure/opportunity
- Partner with Commercial teams on designing and implementing sales incentive plan
Benefits
- Oversee employee benefits programs including health, dental, vision, life, disability, recognition, wellness, deferred compensation and relocation benefits by leveraging external vendors
- Annual evaluation to ensure high-quality and competitive health and wellness offerings
- Monitor benefits trends, analyze utilization and recommend enhancements to improve employee satisfaction and retention
- Manage annual open enrollment activities, including system readiness, communication/training strategy and issue resolution
- Lead and coordinate benefits-related audits, including regulatory compliance (ERISA, ACA, COBRA)
- Maintain benefits documentation, policies, and candidate/employee-facing resources
Experience
- Minimum of 5 year’s experience in biotech or pharma compensation
- Title is negotiable, but dependent on experience
- Experience with benefits preferred, but not mandatory
- Professional certifications such as CCP (Certified Compensation Professional) or GRP (Global Remuneration Professional) preferred, but not mandatory
Similar Jobs
What We Do
Cogent Biosciences is a biotechnology company developing real solutions to treat genetically driven diseases. With a focus on rational drug discovery and development, we are leveraging validated biology to advance precision therapies designed to address the true underlying drivers of disease and provide real hope for patients. Cogent’s lead therapeutic candidate, bezuclastinib (CGT9486), is a precision kinase inhibitor designed to selectively and potently inhibit the KIT D816V mutation. This mutation is responsible for driving a rare and serious condition called Systemic Mastocytosis which can severely impact many different tissues and organs in the body. We are also studying CGT9486 to treat advanced gastrointestinal stromal tumors (GIST), which have a strong dependence on oncogenic KIT signaling.
